Published in Clin Rheumatol on April 11, 2010
Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol (2012) 0.90
Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis. J Hum Genet (2015) 0.90
Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med (2013) 0.82
Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol (2013) 0.79
Effect of Anti-Cyclic Citrullinated Peptide and HLA-DRB1 Subtypes on Clinical Disease Activity Index in Rheumatoid Arthritis Patients. J Clin Diagn Res (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum (1987) 14.21
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum (2005) 5.18
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis (2004) 3.23
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther (2004) 2.72
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther (2005) 2.69
The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum (2006) 2.46
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum (2004) 2.25
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum (2004) 2.08
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am (1992) 1.61
HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol (1995) 1.58
Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum (2004) 1.50
Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther (2006) 1.40
Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum (1991) 1.36
Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest (1995) 1.24
The relationship between HLA-DRB1 alleles and disease subsets of rheumatoid arthritis in Japanese. Br J Rheumatol (1997) 1.17
The shared epitope and severity of rheumatoid arthritis. Rheum Dis Clin North Am (2002) 1.17
The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum Dis Clin North Am (1992) 1.15
Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol (1995) 1.14
HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum (1997) 1.12
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol (2002) 1.07
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis (2010) 1.05
The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis (2005) 1.03
Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) (2006) 0.95
Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis. Rheum Dis Clin North Am (2002) 0.89
Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol (2006) 0.82
The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. Ann Rheum Dis (2008) 0.80
HLA-DRB1*04 alleles in Japanese rheumatoid arthritis patients with AA amyloidosis. J Rheumatol (2006) 0.76
Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis. Clin Rheumatol (2008) 0.76
Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset. J Rheumatol (2002) 0.75
Outcome of radical multiple synovectomy as a novel surgical treatment for refractory rheumatoid arthritis: implication of HLA-DRB1*0405 in post-operative results. Clin Exp Rheumatol (1997) 0.75
Relationship between duration of rheumatoid arthritis before knee joint surgery and HLA-DRB1 alleles: a retrospective study. J Rheumatol (1997) 0.75
Derivation of 2 categories of plasmacytoid dendritic cells in murine bone marrow. Blood (2005) 1.58
Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem (2002) 1.46
Tracing the first waves of lymphopoiesis in mice. Development (2006) 1.28
Unique properties of fetal lymphoid progenitors identified according to RAG1 gene expression. Immunity (2003) 1.20
T1ρ and T2 mapping reveal the in vivo extracellular matrix of articular cartilage. J Magn Reson Imaging (2011) 1.18
Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res (2011) 1.17
Arthroscopic repair of traumatic combined rotator cuff tears involving the subscapularis tendon. J Bone Joint Surg Am (2007) 1.16
Generation and characterization of severe combined immunodeficiency rats. Cell Rep (2012) 1.04
Enhanced apoptotic and reduced protective response in chondrocytes following endoplasmic reticulum stress in osteoarthritic cartilage. Int J Exp Pathol (2011) 0.98
Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6. J Bone Miner Res (2011) 0.97
The effect of a local application of fibroblast growth factor-2 on tendon-to-bone remodeling in rats with acute injury and repair of the supraspinatus tendon. J Shoulder Elbow Surg (2009) 0.96
Reconstruction of large rotator-cuff tears with acellular dermal matrix grafts in rats. J Shoulder Elbow Surg (2008) 0.95
Class IA phosphatidylinositol 3-kinase regulates osteoclastic bone resorption through protein kinase B-mediated vesicle transport. J Bone Miner Res (2012) 0.95
The effects of fibroblast growth factor-2 on rotator cuff reconstruction with acellular dermal matrix grafts. Arthroscopy (2009) 0.92
Detecting ICRS grade 1 cartilage lesions in anterior cruciate ligament injury using T1ρ and T2 mapping. Eur J Radiol (2013) 0.91
Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J Biol Chem (2009) 0.90
Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys. J Pharmacol Sci (2008) 0.86
Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J Bone Miner Res (2015) 0.86
Animal models of pathologic calcification. Curr Opin Rheumatol (2002) 0.84
Intracellular accumulation of advanced glycation end products induces apoptosis via endoplasmic reticulum stress in chondrocytes. FEBS J (2013) 0.83
Epigenetic regulation of osteoclast differentiation. Ann N Y Acad Sci (2011) 0.83
Familial Mediterranean fever occurring in an elderly Japanese woman with recent-onset rheumatoid arthritis. Intern Med (2013) 0.82
Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. J Bone Miner Metab (2013) 0.82
Regulation of bone resorption and sealing zone formation in osteoclasts occurs through protein kinase B-mediated microtubule stabilization. J Bone Miner Res (2013) 0.81
An anatomic study of the subscapularis insertion to the humerus: the subscapularis footprint. Arthroscopy (2008) 0.80
Synthesis of poly(amidoamine) dendron-bearing lipids with poly(ethylene glycol) grafts and their use for stabilization of nonviral gene vectors. Bioconjug Chem (2007) 0.79
Anti-apoptotic Bcl-2 family member Mcl-1 regulates cell viability and bone-resorbing activity of osteoclasts. Bone (2013) 0.77
Application of electrolysis to inactivation of antibacterials in clinical use. Ecotoxicol Environ Saf (2013) 0.75
Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicol Environ Saf (2011) 0.75
Painful heterotopic pacinian corpuscle in the hand: a report of three cases. Hand Surg (2011) 0.75
Mechanism analysis of long-term graft survival by monocarboxylate transporter-1 inhibition. Transplantation (2010) 0.75
Evaluation of disinfective potential of reactivated free chlorine in pooled tap water by electrolysis. J Microbiol Methods (2004) 0.75
The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates. Transplantation (2016) 0.75
Evaluation of an electrolysis apparatus for inactivating antineoplastics in clinical wastewater. Chemosphere (2008) 0.75
Application of electrolysis for inactivation of an antiviral drug that is one of possible selection pressure to drug-resistant influenza viruses. J Virol Methods (2013) 0.75